Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 6

Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

March 12, 2025

Benjamin P. Levy, MD, Misty D. Shields, MD, PhD

Panelists discuss how, in clinical practice, ADAURA (osimertinib) and ALINA (alectinib) are integrated based on EGFR/ALK status, stage, and recurrence risk. Adjuvant therapy duration is typically 3 years. Circulating tumor DNA (ctDNA), minimal residual disease (MRD) from ADAURA (ASCO 2024, Abs 8005) may refine treatment decisions by detecting MRD.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: An Expert Insights on Recent Advancements in LS-SCLC

EP. 2: The Key Updates in the Treatment of ES-SCLC

EP. 3: An Expert Perspectives on Tarlatamab in ES-SCLC

EP. 4: Looking Ahead With SCLC: ADCs and Other Novel Agents

EP. 5: The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

Now Viewing

EP. 6: Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP. 7: The New Targeted Approaches in Unresectable Early-Stage NSCL

EP. 8: Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

EP. 9: Expert Insights for the Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond

EP. 10: Latest Advances in Management of Advanced NSCLC with ALK or ROS1 Mutations

EP. 11: The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

EP. 12: Tailoring Immunotherapy Strategies for the Advanced NSCLC

Video content above is prompted by the following:

How are you incorporating the ADAURA and ALINA regimens into your clinical practice, and what factors influence your patient selection?
What is your anticipated duration of therapy for patients receiving adjuvant osimertinib or alectinib?
What is the role of ctDNA in early-stage NSCLC, and how may it guide adjuvant therapy decisions? (MRD analysis from ADAURA: John T, ASCO 2024. Abs 8005.